The National Academies of Sciences, Engineering, and Medicine today released for public comment a discussion draft of a preliminary framework to assist policymakers in planning for equitable allocation of a vaccine against COVID-19. The committee that developed the draft framework was formed in July in response to a request from the National Institutes of Health and Centers for Disease Control and Prevention.

The committee defined the foundational principles, primary goal and criteria for determining an equitable allocation framework. For the initial period when vaccine demand exceeds supply, the committee recommends a four-phased approach guided by evidence to achieve the primary goal of maximizing societal benefit by reducing morbidity and mortality caused by the transmission of COVID-19. As the supply of vaccine increases, the framework says it will be incrementally phased in, so that some people or groups of people will receive it earlier than others. The discussion draft outlines the phases and rationale for prioritizing each group included in each phase.

The public comment period will be open from noon ET Sept. 1 until 11:59 p.m. ET Sept. 4. Commenters will be able to download and review the discussion draft before submitting a comment through a form on the NASEM website. The committee’s final report is expected early this fall.
 

Related News Articles

Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…